Drug intelligence / Profile preview

XYL-300X

Development stage: Preclinical
Lead developer: Xylo Bio
Modality: Small Molecules

Overview

XYL-300X is a preclinical, non-hallucinogenic small molecule drug candidate being developed for the treatment of substance use disorders. It is designed to act as a 5-HT2A receptor agonist, targeting the serotonin 2A (5-HT2A) receptor, which is implicated in neuropsychiatric and substance abuse conditions. The drug is under development by Xylo Bio and has not yet entered clinical trials[1][8].

Targets

HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on XYL-300X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XYL-300X.

Explore the full profile